ASX:MYX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. More Details


Snowflake Analysis

Adequate balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Mayne Pharma Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.5%

MYX

-8.8%

AU Pharmaceuticals

-1.4%

AU Market


1 Year Return

-41.8%

MYX

-30.5%

AU Pharmaceuticals

-7.1%

AU Market

Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned -28.5% over the past year.

Return vs Market: MYX underperformed the Australian Market which returned -6.9% over the past year.


Shareholder returns

MYXIndustryMarket
7 Day-1.5%-8.8%-1.4%
30 Day-11.1%-7.9%3.4%
90 Day-22.0%-6.1%3.8%
1 Year-41.8%-41.8%-30.4%-30.5%-3.7%-7.1%
3 Year-53.6%-53.6%-38.7%-39.6%16.9%2.1%
5 Year-67.3%-68.9%-31.7%-35.5%46.0%15.6%

Price Volatility Vs. Market

How volatile is Mayne Pharma Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mayne Pharma Group undervalued compared to its fair value and its price relative to the market?

47.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MYX (A$0.32) is trading below our estimate of fair value (A$0.61)

Significantly Below Fair Value: MYX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MYX is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.

PE vs Market: MYX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYX is good value based on its PB Ratio (0.5x) compared to the AU Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is Mayne Pharma Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

106.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: MYX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MYX's is expected to become profitable in the next 3 years.

Revenue vs Market: MYX's revenue (11.2% per year) is forecast to grow faster than the Australian market (4.6% per year).

High Growth Revenue: MYX's revenue (11.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MYX's Return on Equity is forecast to be low in 3 years time (6%).


Next Steps

Past Performance

How has Mayne Pharma Group performed over the past 5 years?

-55.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYX is currently unprofitable.

Growing Profit Margin: MYX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYX is unprofitable, and losses have increased over the past 5 years at a rate of 55.9% per year.

Accelerating Growth: Unable to compare MYX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (117.8%).


Return on Equity

High ROE: MYX has a negative Return on Equity (-9.07%), as it is currently unprofitable.


Next Steps

Financial Health

How is Mayne Pharma Group's financial position?


Financial Position Analysis

Short Term Liabilities: MYX's short term assets (A$490.9M) exceed its short term liabilities (A$219.3M).

Long Term Liabilities: MYX's short term assets (A$490.9M) do not cover its long term liabilities (A$563.6M).


Debt to Equity History and Analysis

Debt Level: MYX's debt to equity ratio (37.3%) is considered satisfactory.

Reducing Debt: MYX's debt to equity ratio has increased from 18.8% to 37.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable MYX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: MYX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 13.9% per year.


Next Steps

Dividend

What is Mayne Pharma Group current dividend yield, its reliability and sustainability?

0.63%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MYX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: MYX is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Scott Richards (56 yo)

8.67yrs

Tenure

AU$2,960,427

Compensation

Mr. Scott Anthony Richards has been the Chief Executive Officer and Managing Director of Mayne Pharma Group Limited since February 13, 2012. Mr. Richards joined Mayne Pharma in February 2012. He served as ...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD2.11M) is above average for companies of similar size in the Australian market ($USD693.56K).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Scott Richards
MD, CEO & Executive Director8.67yrsAU$2.96m1.54%
A$ 8.4m
Peter Paltoglou
Chief Financial Officer0.58yrAU$1.02m0.47%
A$ 2.6m
Stefan Cross
President of International Operations3.75yrsAU$1.01m0%
A$ 0
Lisa Pendlebury
Vice President of Investor Relations & Communications4.92yrsAU$456.63k0%
A$ 0
Kate Rintoul
Executive VP & General Counsel7.75yrsAU$767.48k0%
A$ 0
Andrew Herdman
Vice President of Group Human Resources2.08yrsno datano data
Brant Schofield
Executive Vice President of Specialty Brands Division2yrsAU$1.29m0%
A$ 0
Daniel Moore
Executive Vice President of Generics Products Division1.08yrsno datano data
Brenton Walter
Financial Controller16.25yrsno datano data
John Ross
President of Mayne Pharma USA3.75yrsAU$1.21m0%
A$ 0
Laura Loftus
Associate General Counsel & Company Secretary0.58yrno datano data
Peter Truelove
National Sales & Marketing Director8.42yrsAU$101.58kno data

3.8yrs

Average Tenure

54yo

Average Age

Experienced Management: MYX's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Scott Richards
MD, CEO & Executive Director8.67yrsAU$2.96m1.54%
A$ 8.4m
Ian Scholes
Independent Non-Executive Director13yrsAU$153.30k0.13%
A$ 701.5k
Roger Corbett
Independent Chairman9.75yrsAU$303.75k0.62%
A$ 3.4m
Bruce Mathieson
Independent Non Executive Director13.67yrsAU$131.40k6.29%
A$ 34.3m
Frank Condella
Independent Non-Executive Director2.42yrsAU$213.99k0.020%
A$ 111.6k
Bruce Robinson
Independent Non-Executive Director6.17yrsAU$147.83kno data
Patrick Blake
Independent Non-Executive Director2.33yrsAU$205.46k0.015%
A$ 84.5k
Nancy Dolan
Independent Non-Executive Director4.08yrsAU$142.35k0.0061%
A$ 33.1k

7.4yrs

Average Tenure

65.5yo

Average Age

Experienced Board: MYX's board of directors are considered experienced (7.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MYX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.4%.


Top Shareholders

Company Information

Mayne Pharma Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mayne Pharma Group Limited
  • Ticker: MYX
  • Exchange: ASX
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$545.697m
  • Shares outstanding: 1.68b
  • Website: https://www.maynepharma.com

Number of Employees


Location

  • Mayne Pharma Group Limited
  • 1538 Main North Road
  • Salisbury South
  • South Australia
  • 5106
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYXASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJun 2007
HG6DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2007
MAYN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2007
MYXCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJun 2007

Biography

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company o ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 10:37
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.